Green Cross Holdings Corporation (005250.KS)
KRW 12720.0
(0.32%)
KRW 12720.0
(0.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 66.84 Billion KRW | -55.0% |
| 2022 | 180.23 Billion KRW | -33.47% |
| 2021 | 196.1 Billion KRW | 67.5% |
| 2020 | 182.32 Billion KRW | 61.95% |
| 2019 | 68.33 Billion KRW | -5.94% |
| 2018 | 96.59 Billion KRW | -33.11% |
| 2017 | 153.16 Billion KRW | -2.42% |
| 2016 | 134.35 Billion KRW | -19.32% |
| 2015 | 141.87 Billion KRW | 12.92% |
| 2014 | 138.01 Billion KRW | 47.03% |
| 2013 | 115.22 Billion KRW | 12.48% |
| 2012 | 73.13 Billion KRW | -33.26% |
| 2011 | 123.28 Billion KRW | -21.79% |
| 2010 | 187.25 Billion KRW | 21.63% |
| 2009 | 154.65 Billion KRW | 220.81% |
| 2008 | 79.04 Billion KRW | -37.61% |
| 2007 | 81.82 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 36.58 Billion KRW | 425.37% |
| 2024 Q1 | -5.9 Billion KRW | -429.67% |
| 2023 Q1 | -9.09 Billion KRW | -2232.99% |
| 2023 Q3 | 170.96 Billion KRW | 1.88% |
| 2023 Q2 | 167.8 Billion KRW | 1945.57% |
| 2023 Q4 | 1.89 Billion KRW | -98.89% |
| 2023 FY | - KRW | -55.0% |
| 2022 Q2 | 30.76 Billion KRW | -82.66% |
| 2022 Q3 | 66.51 Billion KRW | 116.21% |
| 2022 Q4 | 426.28 Million KRW | -99.36% |
| 2022 Q1 | 177.43 Billion KRW | 146.65% |
| 2022 FY | - KRW | -33.47% |
| 2021 Q1 | 53.48 Billion KRW | 478.16% |
| 2021 Q4 | 71.93 Billion KRW | -28.37% |
| 2021 FY | - KRW | 67.5% |
| 2021 Q3 | 100.43 Billion KRW | 417.54% |
| 2021 Q2 | 19.4 Billion KRW | -63.72% |
| 2020 Q2 | 45.23 Billion KRW | 113.81% |
| 2020 Q1 | 21.15 Billion KRW | 413.29% |
| 2020 Q3 | 75.84 Billion KRW | 67.68% |
| 2020 FY | - KRW | 61.95% |
| 2020 Q4 | -14.14 Billion KRW | -118.65% |
| 2019 Q2 | 19.69 Billion KRW | -14.19% |
| 2019 Q4 | -6.75 Billion KRW | -112.38% |
| 2019 FY | - KRW | -5.94% |
| 2019 Q3 | 54.52 Billion KRW | 176.93% |
| 2019 Q1 | 22.94 Billion KRW | 174.19% |
| 2018 Q2 | 21.78 Billion KRW | -30.1% |
| 2018 Q3 | 34.8 Billion KRW | 59.75% |
| 2018 FY | - KRW | -33.11% |
| 2018 Q1 | 31.16 Billion KRW | 275.65% |
| 2018 Q4 | 8.36 Billion KRW | -75.95% |
| 2017 FY | - KRW | -2.42% |
| 2017 Q4 | 8.29 Billion KRW | -85.35% |
| 2017 Q3 | 56.62 Billion KRW | 3.56% |
| 2017 Q2 | 54.68 Billion KRW | 126.86% |
| 2017 Q1 | 24.1 Billion KRW | -56.0% |
| 2016 Q1 | 18.1 Billion KRW | 80.47% |
| 2016 Q2 | 34.78 Billion KRW | 92.17% |
| 2016 Q3 | 39.59 Billion KRW | 13.81% |
| 2016 Q4 | 54.78 Billion KRW | 38.36% |
| 2016 FY | - KRW | -19.32% |
| 2015 FY | - KRW | 12.92% |
| 2015 Q4 | 10.03 Billion KRW | -89.99% |
| 2015 Q3 | 100.25 Billion KRW | 112.23% |
| 2015 Q2 | 47.23 Billion KRW | 88.9% |
| 2015 Q1 | 25 Billion KRW | 26.16% |
| 2014 FY | - KRW | 47.03% |
| 2014 Q3 | 65.69 Billion KRW | 130.33% |
| 2014 Q2 | 28.52 Billion KRW | -40.08% |
| 2014 Q1 | 47.6 Billion KRW | 302.46% |
| 2014 Q4 | 19.82 Billion KRW | -69.83% |
| 2013 Q4 | 11.82 Billion KRW | -76.45% |
| 2013 FY | - KRW | 12.48% |
| 2013 Q1 | 21.43 Billion KRW | 400.68% |
| 2013 Q2 | 26.46 Billion KRW | 23.47% |
| 2013 Q3 | 50.21 Billion KRW | 89.77% |
| 2012 Q3 | 51.15 Billion KRW | 110.28% |
| 2012 Q2 | 24.32 Billion KRW | -17.15% |
| 2012 Q1 | 29.36 Billion KRW | 23.52% |
| 2012 FY | - KRW | -33.26% |
| 2012 Q4 | -7.12 Billion KRW | -113.93% |
| 2011 Q1 | 41.52 Billion KRW | 0.0% |
| 2011 Q3 | 113.65 Billion KRW | 239.89% |
| 2011 Q4 | 23.76 Billion KRW | -79.09% |
| 2011 Q2 | 33.43 Billion KRW | -19.47% |
| 2011 FY | - KRW | -21.79% |
| 2010 Q2 | 3.35 Billion KRW | -61.86% |
| 2010 Q3 | 1.44 Billion KRW | -56.82% |
| 2010 FY | - KRW | 21.63% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 8.78 Billion KRW | 0.0% |
| 2009 Q3 | 4.38 Billion KRW | 119.53% |
| 2009 Q2 | 1.99 Billion KRW | 161.95% |
| 2009 Q1 | 762.34 Million KRW | 0.0% |
| 2009 FY | - KRW | 220.81% |
| 2009 Q4 | - KRW | -100.0% |
| 2008 Q3 | 1.71 Billion KRW | 114.43% |
| 2008 Q2 | -11.9 Billion KRW | -637.18% |
| 2008 Q1 | 2.21 Billion KRW | 0.0% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | - KRW | -37.61% |
| 2007 Q1 | -3.64 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q2 | -6.92 Billion KRW | -89.71% |
| 2007 Q3 | 1.22 Billion KRW | 117.64% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | -326.637% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 39.13% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | -691.927% |
| Green Cross Corporation | 109.81 Billion KRW | 39.13% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 204.934% |
| Celltrion, Inc. | 897.26 Billion KRW | 92.551% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 95.831% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | -193.461% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | 401.023% |
| Prestige BioPharma Limited | -31.04 Billion KRW | 315.287% |